Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-RingSynonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Xanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigationalSchizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing
Categories: MATE 2-K Inhibitors, MATE 1 InhibitorsUrolithin A
go.drugbank.com/drugs/DB15464ExperimentalUrolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.[A179494]
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: Uro-A, Urolithin AZelenirstat
go.drugbank.com/drugs/DB15567InvestigationalZelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https://pacylex.com).
Synonyms: 2,6-Dichloro-N-(1,5-dimethyl-3-(2-methylpropyl)-1H-pyrazol-4-yl)-4-(2-(1-piperazinyl)-4-pyridinyl)benzenesulfonamide, 2,6-Dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamideAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-TMC-310911
go.drugbank.com/drugs/DB15623InvestigationalTMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for … [L12045] It is being investigated for use in HIV-1 infections.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingZilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigationalZilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.
Synonyms: N2-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-L-VALYL-L-TYROSYL-3-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-L-ALANYL-L-.ALPHA., .-(2-(((4S)-4-CARBOXY-1-OXO-4-(1-OXOHEXADECYL)BUTYL)AMINO)ETHYL)-.OMEGA.-HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.Products: Zılbrysq 16,6 mg/0,416 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet), Zılbrysq 23 mg/0,574 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet)Ravidasvir
go.drugbank.com/drugs/DB15652InvestigationalRavidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).
Categories: Heterocyclic Compounds, 2-RingIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency. … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.
Categories: Heterocyclic Compounds, 2-RingSynonyms: 4'-ethynyl-2-fluoro-2'-deoxyadenosine